Eliana Merle
Stock Analyst at UBS
(0.95)
# 2191
Out of 5,370 analysts
97
Total ratings
42.55%
Success rate
2.92%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
RAPT RAPT Therapeutics | Maintains: Neutral | 16 8 | 1.03 | 676.7% | 3 | May 22, 2025 | |
ARVN Arvinas | Maintains: Buy | 74 21 | 7.38 | 184.55% | 4 | May 15, 2025 | |
KYMR Kymera Therapeutics | Maintains: Buy | 72 70 | 46.85 | 49.41% | 3 | May 13, 2025 | |
MRNA Moderna | Maintains: Buy | 78 70 | 26 | 169.23% | 7 | May 2, 2025 | |
MDGL Madrigal Pharmaceuti... | Maintains: Strong Buy | 441 458 | 284.98 | 60.71% | 4 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 13 12 | 5.54 | 116.61% | 2 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 65 72 | 41.04 | 75.44% | 3 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 44 | 18.32 | 140.17% | 8 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 109 113 | 56.19 | 101.1% | 2 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 25 38 | 10.03 | 278.86% | 3 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 42 109 | 55.47 | 96.5% | 4 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 5 3 | 1.5 | 46.67% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 65 71 | 39.65 | 79.07% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 196 | 177.69 | 10.3% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 28 | 10.22 | 173.97% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 12 | 7.3 | 64.38% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 3 | 3.32 | -9.64% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 26 | 6.84 | 280.12% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 23 33 | 23.89 | 38.13% | 4 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 97 131 | 106.15 | 23.41% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 253 288 | 308.78 | -6.73% | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 3 5 | 3.77 | 32.63% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 19 18 | 4.01 | 348.88% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 25 33 | n/a | n/a | 7 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 45 42 | 15.11 | 177.96% | 4 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 34 40 | n/a | n/a | 2 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 19 8 | 1.28 | 525% | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 22 | 4.82 | 356.43% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 51 47 | 9.14 | 414.22% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 9 | n/a | n/a | 1 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 16 | 6.05 | 164.46% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 192 134 | 28.82 | 364.95% | 3 | Aug 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 121 | n/a | n/a | 1 | Apr 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 10 | n/a | n/a | 1 | Jan 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 57 68 | n/a | n/a | 2 | Oct 22, 2018 |